SEC Comment Letter 0000000000-23-000956 to CASI Pharmaceuticals, Inc. (CIK 0000895051)
CASI Pharmaceuticals, Inc. (CIK 0000895051)
Date: Jan. 30, 2023 · CIK: 0000895051 · Accession: 0000000000-23-000956
AI Filing Summary & Sentiment
File numbers found in text: 000-20713
Letter
United States securities and exchange commission logo January 30, 2023 Larry Zhang Principal Financial Officer CASI Pharmaceuticals, Inc. 9620 Medical Center Drive Suite 300 Rockville, MD 20850 Re:CASI Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2021 Form 10-Q for the Interim Period Ended September 30, 2022 File No. 000-20713 Dear Larry Zhang: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
January 30, 2023
Larry Zhang
Principal Financial Officer
CASI Pharmaceuticals, Inc.
9620 Medical Center Drive
Suite 300
Rockville, MD 20850
Re:CASI Pharmaceuticals, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2021
Form 10-Q for the Interim Period Ended September 30, 2022
File No. 000-20713
Dear Larry Zhang:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences